DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Losmapimod is an investigational drug.
There have been 10 clinical trials for Losmapimod. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are GlaxoSmithKline, Fulcrum Therapeutics, and Cambridge University Hospitals NHS Foundation Trust.
There are eight US patents protecting this investigational drug and seventy-three international patents.
Recent Clinical Trials for Losmapimod
|Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)||Fulcrum Therapeutics||Phase 2|
|Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1||Fulcrum Therapeutics||Phase 2|
|Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Phase 2|
Top disease conditions for Losmapimod
Top clinical trial sponsors for Losmapimod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Losmapimod||Start Trial||Nicotinamide derivatives useful as p38 inhibitors.||SmithKline Beecham Corporation (Philadelphia, PA)||Start Trial|
|Losmapimod||Start Trial||Nicotinamide derivatives useful as p38 inhibitors||SmithKline Beecham Corporation (Philadelphia, PA)||Start Trial|
|Losmapimod||Start Trial||Nicotinamide derivatives useful as p38 inhibitors||GlaxoSmithkline LLC (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|